CH 4987655,
CH-4987655,
CH4987655,
RO4987655,
RO4987655,
874101-00-5,
CH-4987655,
RO-4987655,
UNII-I3733P75ML,
CH4987655,
CHEMBL1614766,
I3733P75ML,
3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)amino]-N-(2-Hydroxyethoxy)-5-[(3-Oxo-1,2-Oxazinan-2-Yl)methyl]benzamide,
3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-((3-oxomorpholino)methyl)benzamide,
C20H19F3IN3O5,
3,4-Difluoro-2-(2-fluoro-4-iodo-anilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide,
3orn,
FIMYFEGKMOCQKT-UHFFFAOYSA-N,
GTPL9910,
SCHEMBL1562083,
SYN1188,
BCP12182,
EX-A2312,
4014AH,
BDBM50338038,
ZINC43103796,
AKOS005266648,
CS-2715,
DB12933,
SB16732,
r-7167,
compound 24 [PMID: 21316218],
3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxo-2-oxazinanyl)methyl]benzamide,
AS-16322,
HY-14719,
B3261,
RO 4987655,
US8575391, 334,
RO4987655; CH-4987655,
3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)-benzamide,
3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide,
3OR,
Benzamide, 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(tetrahydro-3-oxo-2H-1,2-oxazin-2-yl)methyl]-,
D09GHB,
MEK inhibitors (solid tumor), Roche,
CID11548630,
CID 11548630,
RO-04927350,
A13272,